Medical Device · Renal Health

Continuous
monitoring for
better renal care.

QuinSense is developing a wearable biosensor platform designed to give dialysis patients and their physicians real-time visibility into kidney health.

Learn more
Live
Normal
Trend
Stable ↗
Alert
None

Patients deserve
real-time insight.

Chronic kidney disease affects tens of millions of Americans. Today, monitoring relies on infrequent clinical visits and reactive care — leaving patients and physicians without the continuous data needed to intervene early and reduce hospitalizations.

35M
Americans with chronic kidney disease
$45B
Spent annually on ESRD care by Medicare
554K
Patients currently dependent on dialysis
1.7×
Average hospitalizations per patient per year

Wearable.
Continuous.
Actionable.

We are building a proprietary wearable biosensor platform that provides continuous biomarker tracking — giving patients and clinicians the data they need to make timely, informed care decisions and reduce the burden of late-stage interventions.

Continuous Sensing

Our device tracks clinically relevant kidney biomarkers around the clock, replacing periodic snapshots with a continuous stream of actionable physiological data.

Predictive Alerts

Trend analysis and intelligent alerting help patients and physicians identify physiological risk events before they escalate into hospitalizations.

Connected Platform

A companion app delivers live readings and longitudinal data to both patients and their care teams, enabling coordinated care from anywhere.

A clear gap
in the market.

No wearable device currently offers continuous, kidney-specific biomarker monitoring. QuinSense is positioned to fill that gap — enabling proactive care where only reactive care exists today.

$0
True CompetitorsNo wearable currently combines continuous monitoring with kidney-specific biomarkers
~68%
Of ESRD Patients Addressable554K dialysis patients represent our initial target within a 808K serviceable market
39%
Of Hospitalizations PreventableThrombotic complications — often tied to missed warning signs — drive nearly 4 in 10 admissions

Built by specialists
across every discipline.

QuinSense brings together expertise in bioelectronics, mechanical engineering, software, clinical science, finance, and regulatory affairs — all united around a single mission.

EP
Evan Park
Chief Executive Officer
JM
Jacob Murphy
Chief Technology Officer
BB
Blake Brown
Chief Operating Officer
JD
Jason Deng
Director of Clinical Systems & Translational Science
AM
Alan Motoki
Director of Product Strategy & Regulatory Affairs

Interested in
what we're building?

Whether you're a potential partner, clinician, investor, or patient advocate — we'd love to hear from you.

admin@quinsense.com

Houston, Texas · Seed Stage

Early-stage. Mission-driven.

QuinSense is a pre-clinical medical device startup focused on transforming how dialysis patients monitor and manage their kidney health. We are actively seeking strategic partnerships, clinical collaborators, and mission-aligned investors to accelerate our development timeline.

Seed / Pre-Seed Funding Stage